Edition:
India

Axovant Gene Therapies Ltd (AXGT.OQ)

AXGT.OQ on NASDAQ Stock Exchange Global Select Market

3.03USD
12:56am IST
Change (% chg)

$0.06 (+2.02%)
Prev Close
$2.97
Open
$2.98
Day's High
$3.03
Day's Low
$2.98
Volume
21,002
Avg. Vol
45,762
52-wk High
$8.05
52-wk Low
$1.42

Latest Key Developments (Source: Significant Developments)

Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica For Manufacturing And Supply Of Axo-Lenti-Pd
Friday, 31 Jul 2020 

July 31 (Reuters) - Axovant Gene Therapies Ltd ::AXOVANT SIGNS THREE-YEAR CLINICAL SUPPLY AGREEMENT WITH OXFORD BIOMEDICA FOR MANUFACTURING AND SUPPLY OF AXO-LENTI-PD.AXOVANT GENE THERAPIES LTD - SIGNED A THREE-YEAR CLINICAL SUPPLY AGREEMENT WITH OXFORD BIOMEDICA.AXOVANT GENE THERAPIES LTD - OXFORD BIOMEDICA WILL MANUFACTURE GMP BATCHES FOR AXOVANT TO SUPPORT ONGOING AND FUTURE CLINICAL DEVELOPMENT OF AXO-LENTI-PD.AXOVANT GENE THERAPIES LTD - AXOVANT IS CURRENTLY CONDUCTING PHASE 2 SUNRISE-PD TRIAL WITH AXO-LENTI-PD.AXOVANT GENE THERAPIES - OXFORD BIOMEDICA EXPECTS TO MANUFACTURE AXO-LENTI-PD IN COMMERCIAL-SCALE GMP MANUFACTURING FACILITIES INCLUDING OXBOX IN UK.  Full Article

Axovant Gene Therapies Reports Q4 Loss Per Share Of $0.54
Wednesday, 10 Jun 2020 

June 10 (Reuters) - Axovant Gene Therapies Ltd ::AXOVANT ANNOUNCES YEAR-END FINANCIAL RESULTS AND EXPECTED KEY CLINICAL MILESTONES IN Q4 2020.Q4 LOSS PER SHARE $0.54.Q4 EARNINGS PER SHARE ESTIMATE $-0.58 -- REFINITIV IBES DATA.CASH POSITION OF $80.8 MILLION AS OF MARCH 31, 2020 AND EXPECTED RUNWAY INTO SECOND CALENDAR QUARTER OF 2021.DATA FROM COHORT 2 OF SUNRISE-PD PHASE 2 STUDY OF AXO-LENTI-PD IN PARKINSON'S DISEASE EXPECTED IN Q4.  Full Article

Axovant Completes Enrollment Of Low-Dose Cohort In Phase 1/2 Study Of AXO-AAV-GM1, Expands Study
Monday, 8 Jun 2020 

June 8 (Reuters) - Axovant Gene Therapies Ltd ::AXOVANT COMPLETES ENROLLMENT OF LOW-DOSE COHORT IN PHASE 1/2 STUDY OF AXO-AAV-GM1 AND EXPANDS STUDY TO INCLUDE TYPE I (INFANTILE ONSET) PATIENTS WITH GM1 GANGLIOSIDOSIS.AXOVANT GENE THERAPIES LTD - SIX-MONTH DATA FROM LOW-DOSE COHORT OF AXO-AAV-GM1 EXPECTED IN Q4 2020.AXOVANT GENE THERAPIES LTD - EXPECT TO INITIATE HIGH-DOSE COHORT OF AXO-AAV-GM1 IN 2H 2020.  Full Article

Axovant Provides Business, Operations Update During Covid-19 Pandemic
Wednesday, 8 Apr 2020 

April 8 (Reuters) - Axovant Gene Therapies Ltd ::AXOVANT PROVIDES BUSINESS AND OPERATIONS UPDATE DURING THE COVID-19 PANDEMIC.AXOVANT GENE THERAPIES LTD - COMPLETED DOSING OF ALL PATIENTS IN SECOND COHORT OF AXO-LENTI-PD DOSE ESCALATION STUDY.AXOVANT GENE THERAPIES LTD - ARE ON TRACK TO ATTAIN OUR 2020 MILESTONES.AXOVANT GENE THERAPIES LTD - AXOVANT HAS MATERIAL FOR LENTIVIRAL AND AAV PROGRAMS ON HAND TO MEET NEEDS OF OUR ONGOING CLINICAL TRIALS.AXOVANT GENE THERAPIES LTD - PLANS TO UPDATE ITS GUIDANCE IN JUNE 2020 WHEN COMPANY ANNOUNCES FISCAL 2019 YEAR-END RESULTS.  Full Article

Axovant Gene Therapies Posts Q3 Loss Per Share Of $0.62
Monday, 10 Feb 2020 

Feb 10 (Reuters) - Axovant Gene Therapies Ltd ::AXOVANT ANNOUNCES FINANCIAL RESULTS FOR THIRD FISCAL QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2019.Q3 LOSS PER SHARE $0.62.Q3 EARNINGS PER SHARE ESTIMATE $-0.67 -- REFINITIV IBES DATA.  Full Article

Axovant Announces Positive Data On Axo-Lenti-Pd
Monday, 13 Jan 2020 

Jan 13 (Reuters) - Axovant Gene Therapies Ltd ::AXOVANT ANNOUNCES POSITIVE 12-MONTH DATA ON AXO-LENTI-PD AND PROVIDES UPDATES ACROSS GENE THERAPY PIPELINE PROGRAMS.AXOVANT GENE THERAPIES - AXO-LENTI-PD WAS OBSERVED TO BE WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS ATTRIBUTABLE TO GENE THERAPY.AXOVANT GENE THERAPIES LTD - EXPECTS TO INITIATE RANDOMIZED, SHAM-CONTROLLED PART OF SUNRISE-PD PHASE 2 STUDY BY END OF 2020.  Full Article

Axovant Gene Therapies Files For Proposed Mixed Shelf Offering Of Up To $750 Mln
Saturday, 11 Jan 2020 

Jan 10 (Reuters) - Axovant Gene Therapies Ltd ::AXOVANT GENE THERAPIES LTD - FILES FOR PROPOSED MIXED SHELF OFFERING OF UP TO $750 MILLION - SEC FILING.  Full Article

Axovant Announces Amendment To Credit Facility With Hercules Capital
Tuesday, 3 Dec 2019 

Dec 3 (Reuters) - Axovant Gene Therapies Ltd ::AXOVANT ANNOUNCES AMENDMENT TO CREDIT FACILITY WITH HERCULES CAPITAL.AXOVANT GENE THERAPIES - NEW LOAN AMENDMENT REDUCES LOAN OBLIGATION BY 50% WITHOUT PENALTY, ELIMINATES MINIMUM CASH COVENANT.AXOVANT GENE THERAPIES - NEW LOAN AMENDMENT EXTENDS INTEREST-ONLY PERIOD FOR 9 MONTHS.AXOVANT GENE THERAPIES LTD - UNDER NEW LOAN AMENDMENT, DEBT SERVICE BURDEN REDUCED BY ABOUT $2.0 MILLION PER MONTH DURING INTEREST-ONLY PERIOD.  Full Article

Axovant Gene Therapies Receives Orphan Drug Designation From FDA For AXO-AAV-GM1
Monday, 18 Nov 2019 

Nov 18 (Reuters) - Axovant Gene Therapies Ltd ::AXOVANT GENE THERAPIES RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR AXO-AAV-GM1 FOR THE TREATMENT OF GM1 GANGLIOSIDOSIS.AXOVANT GENE THERAPIES LTD - EXPECTS TO ANNOUNCE 6-MONTH DATA FROM PART A OF AXO-AAV-GM1 REGISTRATIONAL PROGRAM IN MID-2020.  Full Article

Axovant Posts Q2 Loss Per Share $0.61
Friday, 8 Nov 2019 

Nov 8 (Reuters) - Axovant Gene Therapies Ltd ::AXOVANT ANNOUNCES CORPORATE UPDATES AND FINANCIAL RESULTS FOR SECOND FISCAL QUARTER ENDED SEPTEMBER 30, 2019.Q2 LOSS PER SHARE $0.61.Q2 EARNINGS PER SHARE ESTIMATE $-1.09 -- REFINITIV IBES DATA.AS OF SEPTEMBER 30, 2019, WE HAD $60.3 MILLION OF CASH AND CASH EQUIVALENTS.AXOVANT - EXPECTS TO PRESENT 3-MONTH DATA FROM SECOND DOSE COHORT OF SUNRISE-PD PHASE 2 STUDY OF AXO-LENTI-PD IN H1 2020.AXOVANT - EXPECTS TO INITIATE A RANDOMIZED, SHAM-CONTROLLED STUDY OF AXO-LENTI-PD BY END OF CALENDAR YEAR 2020.  Full Article

BRIEF-Axovant Gene Therapies Reports Q4 Loss Per Share Of $0.54

* AXOVANT ANNOUNCES YEAR-END FINANCIAL RESULTS AND EXPECTED KEY CLINICAL MILESTONES IN Q4 2020